MYGN (Myriad Genetics)
All Pro Portfolios with MYGN
- Total Pro Portfolios with MYGN:
- BlackRock Health Sciences Instl SHSSX
- Franklin Biotechnology Discovery A - FBDIX
- show more
All Do-It-Yourself Portfolios with MYGN
- Total Do-It-Yourself Portfolios with MYGN:
- stock sniper Portfolio 1
- MJB Portfolio 1
- gplarge Portfolio 1
- Adamantium Partners
- David D
- Jean Thoh Portfolio 1
- Too Good
- josephinefaggiano Portfolio 1
- sandy dandy
- SUPRATRADE BIOTECH
- SUPRATRADE XELLERON 8
- devils advocate
- emag Portfolio 1
- Alzheimer's Index
- SC1887 Portfolio 1
- artemus portfolio I
- madelaney Portfolio 1
- Cash growth
- Powerplay
- techseer Portfolio 1
- ron wilmar Portfolio 1
- perry1
- Mhalal Portfolio 1
- NONAGE II
- Anup Portfolio 1
- powdrslut Portfolio 1
- crabsail Portfolio 1
- hawks nest Portfolio 1
- denladd Portfolio 1
- Michael Fried Portfolio 1
- richyrich1
- BIO & PHARM
- Barron's Research Reports 2-09-2008
- Cach
- Fezwah Portfolio 1
- Fast Money's Biotech Stocks For A Bear Market
- FitzColinGerald
- roy kinsey Portfolio 1
- Finding Eldorado
- Dog Walker
- Fast Money's Biotech Trades
- handson
- Sooze's Picks
- Notable 52-Week Highs and Lows 4-1-09
- jwlowe Portfolio 1
- Cramer's Take on Headline Stocks: June 11
- show more
- 92
- Sportfolio
- Alzheimer's Cure Index
- Steven Clements Portfolio 1
- bill tosetti Portfolio 1
- DD. Portfolio 1
- Gatorman #1
- pit boy contest
- JLP Portfolio
- maryndave
- Amended CNBC Contest Strategy Portfolio
- lmaine7 Portfolio 1
- rinoil Portfolio 1
- NORMAN TURSKY Portfolio 1
- bigboats2 Portfolio 1
- JOHNABBRUZZESI-STOXX ii
- richyrich Portfolio 1
- SUPRATRADE QUANT XI
- Lindawatch
- beecostocks
- GG Portfolio-2
- Win or Lose
- jrnewman Portfolio 1
- BENITRANS CK
- SUPRATRADE "BUY IT ALL TODAY " 0909071845(9.august)
- ahauben Portfolio 1
- joecav50 Portfolio 1
- contrariancat Portfolio 1
- Adizrael
- maumal Portfolio 1
- pickies
- nik's healthcare portfolio
- PART 6 JPMorgan 26th Annual Healthcare Conf 1/9/08..3rd Day Reporting Companies..Nymph Take
- Fast Money's Healthcare Spending Trade
- Fast Money's Alzheimer's Blockbuster Trade
- Fast Money's Medical Breakthrough Trade
- ultimate super technical plus fundamental power portfolio pro
- Utah Stocks
- Fast Money's Biotech Stock Trades
- RAPTOR SPRD BUY LIST 0312102208
- PART 5 JPMorgan 27th Annual Healthcare Conf 1/14/09..3rd Day Reporting Companies..Nymph Take
- Charts of the Week - 2-11-2009
- Lanvin37
- mrm
- Rocket Stocks Research
- Top Takes From RealMoney: May 5
- EBRUNGER Portfolio 1
- News For Selected Stock
- Related stories on theStreet.com
- videos related to etf's
- No videos found
- blogs related to etf's
- No blogs found
Why I Love This Stock |
|
By:EBRUNGER |
Date:08 24 09 |
SPLIT AND GREAT |
|
Not yet rated
Rate now:
|
|
Date:06 11 09 |
|
"I've been too negative on biotech. There's been some insider buying and that's an interesting spec." "Mad Money Lightning Round," 6-10-09 |
|
Not yet rated
Rate now:
|
|
Date:05 05 09 |
|
Adam Feuerstein: "Myriad Genetics (MYGN), the maker of genetic diagnostic tests, including one for breast cancer, came up a $2 million to $3 million short on revenue expectations last night." Read the full article here. |
|
Not yet rated
Rate now:
|
|
By:Art09 |
Date:03 31 09 |
52 Week Highs |
|
Not yet rated
Rate now:
|
|
By:barrons3 |
Date:01 07 09 |
"You might want to keep an eye on Gilead [GILD], Onyx [ONXX], Myriad [MYGN] and Orexigen [OREX], ahead of the JP Morgan healthcare conference on Jan. 12th," adds Mike Huckman. |
|
Not yet rated
Rate now:
|
|
Date:12 30 08 |
|
9 |
|
Not yet rated
Rate now:
|
|
By:barrons3 |
Date:11 12 08 |
Najarian also said keep an eye on Johnson & Johnson(JNJ), Novartis(NVS) and Myriad Genetics(MYGN). |
|
Not yet rated
Rate now:
|
|
By:stockerblog |
Date:08 30 08 |
PE of 65. |
|
Not yet rated
Rate now:
|
|
By:barrons2 |
Date:07 01 08 |
And for strength in diagnostics Najarian says Myriad (MYGN) and Novartis (NVS) look attractive. |
|
Not yet rated
Rate now:
|
|
By:Pro |
Date:11 30 -1 |
Myriad Genetics(MYGN) upgraded to Sector Perform from Underperform at RBC. Price target holds at $13 and reiterates Above Average risk assessment. |
|
Not yet rated
Rate now:
|
|
Why I Hate This Stock |
|
By:gnomeray |
Date:08 02 08 |
Good stock, but overextended in short term. |
|
Not yet rated
Rate now:
|
|
